PFSA vs DXCM

DexCom, Inc.

(DXCM) offers the better valuation at 28. 9x trailing P/E (24. 2x forward), making it the more compelling value choice. Analysts rate DexCom, Inc. (DXCM) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DexCom, Inc.

(DXCM) delivered a total return of -32. 4%, compared to -99. 7% for Profusa, Inc. Common Stock (PFSA). Over 10 years, the gap is even starker: DXCM returned +293. 7% versus PFSA's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DexCom, Inc.

(DXCM) is the lower-risk stock at 1. 06β versus Profusa, Inc. Common Stock's 3. 08β — meaning PFSA is approximately 190% more volatile than DXCM relative to the S&P 500.

On earnings-per-share growth, the picture is similar: DexCom, Inc.

grew EPS 47. 2% year-over-year, compared to 9. 7% for Profusa, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DexCom, Inc.

(DXCM) is the more profitable company, earning 17. 9% net margin versus 0. 0% for Profusa, Inc. Common Stock — meaning it keeps 17. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus 0. 0% for PFSA. At the gross margin level — before operating expenses — DXCM leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DexCom, Inc.

(DXCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 06), +293. 7% 10Y return). Profusa, Inc. Common Stock (PFSA) carries a higher beta of 3. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DXCM: +293. 7%, PFSA: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PFSA is a small-cap quality compounder stock; DXCM is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.